Champions Oncology, Inc. (CSBR)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.65+0.15 (+10.00%)
As of 12:15 PM EDT. Market open.
People also watch:
CRTNKDUSCRMDCAPRALSE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.68
Prev Close1.50
Bid1.65 x 100
Ask1.69 x 400
Day's Range1.55 - 1.90
52wk Range1.11 - 7.50
1y Target EstN/A
Market Cap18.54M
P/E Ratio (ttm)-1.37
Beta-0.86
Volume110,418
Avg Vol (3m)15,695
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year

    HACKENSACK, N.J., July 28, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use ...

  • PR Newswirelast month

    Champions Oncology to Announce Year-End 2016 Financial Results on Thursday, July 28, 2016

    HACKENSACK, N.J., July 25, 2016 /PRNewswire/ -- Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year quarter ended April 30, 2016, on Thursday, July 28, 2016, before market open. The company will host a conference call to discuss the results that day at 8:30 a.m. EDT (5:30 a.m. PDT). An MP3 recoding of the call will be available on the Investor tab of the company's website within 72 hours.

  • PR Newswirelast month

    Champions Oncology Successfully Delivers First AML Study

    HACKENSACK, N.J., July 18, 2016 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the successful completion of its first study in acute myeloid leukemia (AML).  Champions Oncology identified AML as an area of significant unmet customer need and has been pursuing two technological approaches for developing AML models in conjunction with external collaborators.  The first approach involves AML modeling from banked patient samples and the second approach is co-clinical modeling of small volume patient peripheral blood draws. Neal Goodwin, Champions Oncology's Vice President of Corporate Research Development, commented, "These AML models engrafted in mice including in the bone marrow where AML cells are often protected from chemotherapy.